COX-2 specific inhibitors in the management of osteoarthritis of the knee: A placebo-controlled, randomized, double-blind study

Journal of Clinical Rheumatology

Volumn 7, Issue 3, 2001, Pages 151-159

  McKenna, Frank ^a   Weaver, Arthur ^b   Fiechtner, Justus J ^d   Bello, Alfonso E ^c   Fort, John G ^e  

^a TRAFFORD GENERAL HOSPITAL   (United Kingdom)

^b Arthritis Center of Nebraska   (United States)

^c ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e PFIZER INC   (United States)

Author keywords

Celecoxib; Controlled clinical trial; COX 2 specific inhibitors; Osteoarthritis; Rofecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINUSITIS; TOOTH DISEASE; TREATMENT OUTCOME;

EID: 0034990959     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/00124743-200106000-00004     Document Type: Article

References (42)

1. Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: influence of nitric oxide. J Clin Invest 1997;99: 1231-7.
2. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 1998;41: 122-9.
3. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory agents. Am J Med 1993;95(2A suppl): 40S-44S.
4. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91: 12013-7.
5. Masferrer JL, Zweifel BS, Manning PT, Hauser S, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91: 3228-32.
6. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 1997;328: 1069-75.
7. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41: 1591-602.
8. Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000;27: 1876-83.
9. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized, controlled trial. JAMA 1999;282: 1921-8.
10. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354: 2106-11.
11. Silverstein FE, Faich G, Goldstein JL, Hubbard RC, Lonien ME, Yu SS, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000;284: 1247-55.
12. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 specific inhibitor. Am J Gastroenterol 2000;95: 1681-90.
13. Geis GS, Hubbard RC, Woods EM, Lefkowith JB, Yu S, Zhao W, et al. Efficacy of celecoxib, a COX-2 specific inhibitor, in osteoarthritis of the hip [abstract]. Ann Rheum Dis 1999;42(Suppl): 144.
14. McKenna F, Borenstein D, Wendt H, Wallemark G, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30: 11-9.
15. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43: 978-87.
16. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000;160: 1781-7.
17. Ehrich EW, Schnitzer TJ, Mcllwain H, Levy R, Wolfe F, Weisman M, et al. Effect of specific COX-2 inhibition of the knee: a 6-week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol 1999;26: 2438-47.
18. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74: 1095-105.
19. Williams GW, Ettlinger RE, Ruderman EM, Hubbard RC, Lonien ME, Yu SS, et al. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized controlled trial. J Clin Rheumatol 2000;6: 65-74.
20. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29: 1039-49.
21. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140: 659-62.
22. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee: validation-value in comparison and with other assessment tests [published corrections appear in Scand J Rheumatol Suppl 1988;73: 1 and Scand J Rheumatol 1988;17: following 241]. Scand J Rheumatol 1987;65(Suppl): 85-9.
23. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt, LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15: 1833-40.
24. Cooperating Clinics Committee of the American Rheumatism Association. A seven day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965;8: 302-34.
25. Langley GB, Sheppeard H. Problems associated with pain measurement in arthritis: comparisons of visual analogue and verbal rating scales. Clin Exp Rheumatol 1984;2: 231-34.
26. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl 1989;163: 3-8.
27. Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 1999;21: 1497-513.
28. Zhao SZ, McMillen JI, Markenson JA, Dedhiya SD, Zhao WW, Osterhaus JT, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999;19: 1269-78.
29. Smith CJ, Zhang Y, Koboldt CM, Muhammed J, Zweifel BS, Shaffer A, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998;95: 13313-8.
30. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al., for the Rofecoxib Osteoarthritis Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117: 776-83.
31. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282: 1929-33.
32. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160: 2998-3003.
33. Physician drug and diagnosis audit (PDDA). Newtown, Pa: Scott-Levin, Inc., 2000.
34. Bellamy N, Carette S, Ford PM, Kean WF, le Riche NG, Lussier A, et al. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials: results of a consensus development (Delphi) exercise. J Rheumatol 1992;19: 451-7.
35. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol Suppl 1996;220: 124-7.
36. Borda IT, Koff RS, editors. NSAIDs: a profile of adverse events. Philadelphia: Hanley & Belfus, 1992.
37. Whelton A, Fort JG, Puma JA, Normandin D, Bello A, Verburg KM. Cyclooxygenase-2 specific inhibitors and cardiorenal function: a randomized controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8: 85-96.
38. Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992;45: 187-95.
39. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: differences and similarities. N Engl J Med 1991;324: 1716-25.
40. Bodger K, Daly MJ, Heatley RV. Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners. Aliment Pharmacol Ther 1996;10: 889-95.
41. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123: 241-9.
42. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996;156: 1530-6.